In search of lost biomarker for immunotherapy in small-cell lung cancer.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Chemo-immunotherapy is the current standard of care for extensive stage small-cell lung cancer (ES-SCLC), but predictive biomarkers are lacking. In a recent article, the authors report the predictive role of programed death ligand-1 (PD-L1) expression and tissue tumor mutational burden (TMB) on durvalumab ± tremelimumab + platinum-etoposide efficacy.

Keyphrases

small cell lung cancer
healthcare
palliative care
photodynamic therapy
quality improvement
risk factors
cancer therapy
locally advanced
squamous cell carcinoma
radiation therapy
chronic pain